Urinary metabolomic signature of esophageal cancer and Barrett's esophagus

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Davis, Vanessa W ^a   Schiller, Daniel E ^a   Eurich, Dean ^a   Sawyer, Michael B ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

Barrett's esophagus; Diagnosis; Esophageal cancer; Metabolomics; Screening and surveillance; Urine

Indexed keywords

ADULT; ARTICLE; BARRETT ESOPHAGUS; COMPUTER PROGRAM; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; INTERNAL VALIDITY; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MULTIVARIATE ANALYSIS; ORTHOGONAL PARTIAL LEAST SQUARE DISCRIMINANT ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPECTRUM; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; MIDDLE AGED; ROC CURVE;

EID: 84870882718     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-271     Document Type: Article

References (40)

1. Beilstein M, Silberg D. Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma. Gastroenterol Clin N Am 2002, 31:461-479. ix.
2. Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol 2005, 92:151-159. 10.1002/jso.20357, 16299786.
3. Tougeron D, Richer JP, Silvain C. Management of esophageal adenocarcinoma. J Visc Surg 2011, 148:e161-e170. 10.1016/j.jviscsurg.2011.05.008, 21715236.
4. Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 2002, 37:1359-1365. 10.1080/003655202762671215, 12523583.
5. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003, 349:2241-2252. 10.1056/NEJMra035010, 14657432.
6. Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer 1996, 78:1820-1828. 10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO;2-Z, 8859198.
7. Feig BW, Berger DH, Fuhrman GM. The M.D Anderson Surgical Oncology Handbook 2003, Philadelphia: Lippincott Williams & Wilkins, 3.
8. Falk GW. Risk factors for esophageal cancer development. Surg Oncol Clin N Am 2009, 18:469-485. 10.1016/j.soc.2009.03.005, 19500737.
9. Michalak J, Bansal A, Sharma P. Screening and surveillance of Barrett's esophagus. Curr Gastroenterol Rep 2009, 11:195-201. 10.1007/s11894-009-0031-5, 19463219.
10. Ajumobi A, Bahjri K, Jackson C, Griffin R. Surveillance in Barrett's esophagus: an audit of practice. Dig Dis Sci 2010, 55:1615-1621. 10.1007/s10620-009-0917-y, 19669878.
11. Slupsky CM, Rankin KN, Wagner J, Fu H, Chang D, Weljie AM, Saude EJ, Lix B, Adamko DJ, Shah S, Greiner R, Sykes BD, Marrie TJ. Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Anal Chem 2007, 79:6995-7004. 10.1021/ac0708588, 17702530.
12. Eisner R, Stretch C, Eastman T, Xia J, Hau D, Damaraju S, Greiner R, Wishart DS, Baracos V. Learning to predict cancer-associated skeletal muscle wasting from H-NMR profiles of urinary metabolomics. Metabolomics 2011, 7:25-34.
13. McKay RT. Recent advances in solvent suppression for solution NMR: a practical reference. Annual Reports on NMR Spectroscopy 2009, 66:33-76.
14. Keifer PA. 90° pulse width calibrations: how to read a pulse width array. Concepts in Magnetic Resonance 1999, 11:165-180.
15. Kumar A, Ernst RR, Wuthrich K. A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules. Biochem Biophys Res Commun 1980, 95:1-6. 10.1016/0006-291X(80)90695-6, 7417242.
16. Wishart SD. Quantitative metabolomics Using NMR. TrAC Trends Anal Chem 2008, 27:228-237.
17. Weljie AM, Newton J, Mercier P, Carlson E, Slupsky CM. Targeted profiling: quantitative analysis of 1H NMR metabolomics data. Anal Chem 2006, 78:4430-4442. 10.1021/ac060209g, 16808451.
18. Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, Faught W, Sawyer MB. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 2010, 16:5835-5841. 10.1158/1078-0432.CCR-10-1434, 20956617.
19. Stretch C, Eastman T, Mandal R, Eisner R, Wishart DS, Mourtzakis M, Prado CM, Damaraju S, Ball RO, Greiner R, Baracos VE. Prediction of skeletal muscle and fat mass in patients with advanced cancer using a metabolomic approach. J Nutr 2012, 142:14-21. 10.3945/jn.111.147751, 22157537.
20. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007, 6:469-479.
21. Bylesjo M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J. OPLS discriminant analysis: combining the strenghts of PLS-DA and SIMCA classification. J Chemom 2006, 20:341-351.
22. Eriksson L, Johansson E, Kettaneth-Wold N, Trygg J, Wilkstrom C, Wold S. Multivariate and Megavariate Data Analysis Advanced Applications and Extensions (Part I and II) 2006, Umea, Sweden: Umetrics, Inc.
23. Pesarin F. Multivariate Permutation Tests: With Applications in Biostatistics 2001, Wiley, Chichester, New York.
24. Hastie T, Tibshirani R, Friedman JH. The Elements of Statistical Learning: Data Mining, Inference and Prediction: with 200 full-color illustrations 2001, New York: Springer.
25. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010, 8:235-244. quiz e232, 10.1016/j.cgh.2009.10.010, 19850156.
26. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000, 95:1669-1676. 1783835, 10925966.
27. Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000, 46:574-577. 10.1136/gut.46.4.574, 1727885, 10716690.
28. Djukovic D, Baniasadi HR, Kc R, Hammoud Z, Raftery D. Targeted serum metabolite profiling of nucleosides in esophageal adenocarcinoma. Rapid Commun Mass Spectrom 2010, 24:3057-3062. 10.1002/rcm.4739, 20872639.
29. Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr 2012, 26:548-558. 10.1002/bmc.1671, 21773981.
30. Wu H, Xue R, Lu C, Deng C, Liu T, Zeng H, Wang Q, Shen X. Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry. J Chromatogr B, Analyt Technol Biomed Life Sci 2009, 877:3111-3117.
31. Zhang J, Liu L, Wei S, Nagana Gowda GA, Hammoud Z, Kesler KA, Raftery D. Metabolomics study of esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2011, 141:469-475. 10.1016/j.jtcvs.2010.08.025, 20880550.
32. Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T, Kakazu Y, Ishikawa T, Robert M, Nishioka T, Tomita M. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem 2006, 281:16768-16776. 10.1074/jbc.M601876200, 16608839.
33. Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, Psychogios N, Dong E, Bouatra S, Mandal R, Sinelnikov I, Xia J, Jia L, Cruz JA, Lim E, Sobsey CA, Shrivastava S, Huang P, Liu P, Fang L, Peng J, Fradette R, Cheng D, Tzur D, Clements M, Lewis A, De Souza A, Zuniga A, Dawe M, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009, 37:D603-D610. 10.1093/nar/gkn810, 2686599, 18953024.
34. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3:323-327. 10.1186/bcr315, 138696, 11597322.
35. Bachmann J, Ketterer K, Marsch C, Fechtner K, Krakowski-Roosen H, Buchler MW, Friess H, Martignoni ME. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer 2009, 9:255. 10.1186/1471-2407-9-255, 2741486, 19635171.
36. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008, 9:629-635. 10.1016/S1470-2045(08)70153-0, 18539529.
37. Bathe OF, Shaykhutdinov R, Kopciuk K, Weljie AM, McKay A, Sutherland FR, Dixon E, Dunse N, Sotiropoulos D, Vogel HJ. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev 2011, 20:140-147. 10.1158/1055-9965.EPI-10-0712, 21098649.
38. Meisterfeld R, Ehehalt F, Saeger HD, Solimena M. Pancreatic disorders and diabetes mellitus. Exp Clin Endocrinol Diabetes 2008, 116(Suppl 1):S7-S12.
39. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly MA, Forsythe I, Tang P, Shrivastava S, Jeroncic K, Stothard P, Amegbey G, Block D, Hau DD, Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N, Zhang Y, Duggan GE, Macinnis GD, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007, 35:D521-D526. 10.1093/nar/gkl923, 1899095, 17202168.
40. Sihvo EI, Ruohtula T, Auvinen MI, Koivistoinen A, Harjula AL, Salo JA. Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus. J Thorac Cardiovasc Surg 2003, 126:1952-1957. 10.1016/j.jtcvs.2003.08.014, 14688711.